Social media protocol for the biotech investment set
It's important to manage one's reputation on social media. Forbes published an amusing guide on biotech investment etiquette.
Rookie of the Year: Forbes says Keytruda & Opdivo are 2014’s most important new drugs
What was the best new drug of 2014? Forbes‘ Matthew Herper chose two. Herper laid out a solid case for why two new – and highly similar – cancer drugs are standouts this year: Keytruda from Merck and Opdivo from Bristol-Myers Squibb. He writes: These two medicines represent a breakthrough in oncology: unlocking the immune system as a […]
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
EHRs might be forced into interoperability, but it will take time
Electronic health records might actually be forced to enter the era of interoperability, but it’ll take time, a Forbes piece opines. The new, $1.1 trillion”cromnibus” spending bill that Obama signed this month says regulators must decertify EHRS that hinder device interoperability. The law apportions $60 million to help put this into action, stating that regulators “should take steps to […]
Nerd alert: How the mazes of Dungeons & Dragons and pharma R&D compare
The pharma industry just got a hell of a lot nerdier, thanks to a recent Forbes op-ed. It likens the maze-like research and development quagmire to the elf-infused quests seen in fantasy role-playing game Dungeons and Dragons. Chances are slim for biotechs to make it through the high-stakes R&D game alive. Same goes for the goblins of D&D. The story goes: Dungeons […]